| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(10 months ago) | |
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(1 year, 6 months from now) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(1 year, 3 months from now) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(2 years from now) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(5 years from now) | |
Horizant is owned by Azurity.
Horizant contains Gabapentin Enacarbil.
Horizant has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Horizant are:
- US8048917
Horizant was authorised for market use on 06 April, 2011.
Horizant is available in tablet, extended release;oral dosage forms.
Horizant can be used as treatment of moderate-to-severe primary restless leg syndrome in adults, management of postherpetic neuralgia (phn) in adults, treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults.
The generics of Horizant are possible to be released after 10 June, 2029.
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
Market Authorisation Date: 06 April, 2011
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
HORIZANT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic